2.贾晓艳,刘永铭. SGLT2i在射血分数保留心力衰竭中的作用研究进展[J]. 解放军医学杂志,2022,47(2):203-212. 3.De Lorenzi AB, et al. Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibit...
39. Tada K, Gosho M. Increased risk of urinary tract infection and pyelonephritis under concomitant use of sodium-dependent glucose cotransporter 2 inhibitors with antidiabetic, antidyslipidemic, and antihypertensive drugs: an observational study. Fundam...
Recent clinical studies (DAPA-HF, EMPEROR-Reduced and EMPEROR-Preserved, SOLOIST-WHF trial) and meta-analysis have demonstrated that sodium鈥揼lucose cotransporter-2 inhibitors (SGLT2i) are among the first antidiabetic drugs capable of reducing cardiovascular risks related to HF and improving the ...
Although there is no universal conception of HFpEF, and the effects of SGLT2i are considered to be related to the studies’ design, SGLT2i are the only drugs that have shown efficacy in patients with HFpEF. Very recently, in the EMPEROR-Preserved Trial carried out in 5988 patients with HF...
Sano M. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity. J Cardiol. 2018;71(5):471–6. Article PubMed Google Scholar Mogensen UM, Jhund PS, Abraham WT, Desai AS, Dickstein K, Packer M, et al. type of atrial fibrillation and outcomes in patie...
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are now recommended for patients with heart failure, but the mechanisms that underlie the protective role of SGLT2i in cardiac remodeling remain unclear. Aldehyde dehydrogenase 2 (ALDH2) effectively prev
4.Kosiborod M, Cavender MA, Fu AZ, et al. Lower Risk of Heart Failure and Death in Patients initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransp...
Diabetes mellitus (DM) is a major comorbidity of heart failure (HF). Comparing the similarities and differences in disease characteristics and treatment be
Anthracyclines can cause irreversible injury to the myocardium and concerns about anthracycline-induced cardiotoxicity (AIC) limit the use of these effective anticancer drugs.1 In 5% of patients treated with anthracyclines, severe AIC occurs, progressing to chronic heart failure (HF).2 Although AIC ...
3.De Lorenzi AB, et al. Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction. Drugs Context. 2023 Jan 4;12:2022-7-1. 4.Solomon SD, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Eje...